Study: the type of fat, not the amount, fuels pancreatic cancer
A Yale team showed in mice that oleic acid from olive oil speeds pancreatic tumour growth, while omega-3s from fish oil cut the disease burden roughly in half.
- A Yale University team published a mouse study in the journal Cancer Discovery.
- Oleic acid, the main fat in olive oil, sharply accelerated pancreatic tumour growth.
- A diet rich in omega-3s from fish oil cut the disease burden by about 50 percent.
- The findings come from an animal model and are not medical advice for people.
Where the fat on your plate comes from may matter more than how much of it there is, at least in mice prone to pancreatic cancer. A research team at the Yale School of Medicine presented findings on 2 June indicating that oleic acid, the monounsaturated fat most abundant in olive oil, speeds the growth of pancreatic tumours, while omega-3 fats from fish oil push in the opposite direction. The work appeared in the peer-reviewed journal Cancer Discovery.
The result is worth attention because it complicates the familiar story of “good” and “bad” fats. Olive oil has long been treated as a pillar of the Mediterranean diet, so the suggestion that its main component might feed an aggressive tumour calls for careful reading. It is worth stating up front what the study does not claim: this is an experiment in mice, not a recommendation that anyone change how they eat.
What exactly did the researchers measure?
The team compared two diets in mice genetically prone to pancreatic ductal adenocarcinoma, the most common and most lethal form of the disease. A diet rich in oleic acid, a fat also found in peanuts and in sunflower and safflower oil, markedly accelerated tumour growth. A diet built on omega-3 fats from fish oil reduced the disease burden by roughly half.
The difference plays out at the level of the cell. According to the team, oleic acid shields cancer cells from fat oxidation and so helps them survive. Omega-3 fats do the reverse: they trigger ferroptosis, a form of cell death tied to a build-up of fat-related damage. Put plainly, the same food that hands one cell a shield sets a trigger for another.
“It really is the type of fat you take in, not just the total amount of fat,” said Dr Christian Felipe Ruiz, the study’s lead author at Yale University.
The context that gives the finding weight is the disease itself. Pancreatic ductal adenocarcinoma remains one of the bleakest diagnoses in oncology: only about 13 percent of patients survive five years. Any clue to how a tumour’s surroundings, including what we eat, shape its growth carries some weight, if only as a signpost for further research.
Does this change what goes on the plate?
The short answer is no, not yet. The study was led by Dr Ruiz, with Dr Mandar Muzumdar of Yale as senior author, and both stress that the results come from an animal model. Mice are not people, and the fat doses used in a controlled experiment do not map directly onto an everyday diet. The path from a finding in a mouse to any clinical recommendation is long and runs through replication and human trials.
What the study realistically offers is a hypothesis worth testing: that the metabolism of pancreatic tumours responds differently to different kinds of fatty acid. For now that is early-stage science, not a kitchen instruction. No one should drop olive oil or stockpile fish oil capsules on the strength of this paper, least of all people already diagnosed or in treatment.
How cautious do you think we should be before early laboratory findings make their way into everyday dietary advice?
